Adverse effects of media reports on the treatment of osteoporosis
The review focused on the role that media reporting plays in the level of public awareness about osteoporosis and its influence on osteoporosis treatment decisions.
We reviewed the literature on the role of media on three main aspects influencing patient adherence to osteoporosis treatment: the awareness of osteoporosis as a major health problem, the perception of the effectiveness of osteoporosis medications, and the fear of adverse effects with osteoporosis medications.
A review of the literature confirmed what is routinely observed in clinical practice—that media report can strongly influence the level of awareness of osteoporosis and fracture risk. Inadequate and/or incorrect information on osteoporosis in the media are associated with a low level of awareness of the disease. High-risk patients may have a poor understanding of the need for treatment. Alarming information in the media over the last 2 decades regarding effectiveness and safety of long-term osteoporosis treatment is associated with reduction in the use of osteoporosis medications.
There is a gap between the application of clinical recommendations and patient perceptions of osteoporosis and its treatment. There is a need for better education of patients and practitioners aimed at recognizing the serious consequences of fractures and understanding the expected benefits and potential risks of treatment. Media reports that disseminate evidence-based information on the balance of benefits and risks could help to reduce the osteoporosis treatment gap and mitigate the crisis in osteoporosis care.
KeywordsMedia Osteoporosis Fracture Treatment
Compliance with ethical standards
Conflict of Interest
Dr. Cipriani and Dr. Pepe have no financial disclosure and no conflict of interest. Prof. Minisola served as speaker for Abiogen, Amgen, Bruno Farmaceutici, Diasorin, Eli Lilly, and Fujii. He also served in advisory board of Abiogen. He received consultancy from Bruno Farmaceutici. In the past year, Prof. E. Michael Lewiecki has received institutional grant/research support from Amgen, PFEnex, and Mereo; he has served on scientific advisory boards for Amgen, Radius, Shire, Alexion, Ultragenyx, and Sandoz; he serves on the speakers’ bureau for Shire, Alexion, and Radius.
This article contains studies with human participants performed by the authors where ethical approval was obtained.
Informed consent was obtained by all the participants of the aforementioned studies.
- 3.Vescini F, Attanasio R, Balestrieri A, Bandeira F, Bonadonna S, Camozzi V, Cassibba S, Cesareo R, Chiodini I, Francucci CM, Gianotti L, Grimaldi F, Guglielmi R, Madeo B, Marcocci C, Palermo A, Scillitani A, Vignali E, Rochira V, Zini M (2016) Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Investig 39(7):807–834. https://doi.org/10.1007/s40618-016-0434-8 CrossRefGoogle Scholar
- 9.Cipriani C, Pepe J, Bertoldo F, Bianchi G, Cantatore FP, Corrado A, Di Stefano M, Frediani B, Gatti D, Giustina A, Porcelli T, Isaia G, Rossini M, Nieddu L, Minisola S, Girasole G, Pedrazzoni M (2017) The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study. J Endocrinol Investig. https://doi.org/10.1007/s40618-017-0761-4 Google Scholar
- 16.Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM (2013) Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 111(8):1301–1309. https://doi.org/10.1111/j.1464-410X.2012.11777.x CrossRefPubMedGoogle Scholar
- 18.Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28(5):1507–1529. https://doi.org/10.1007/s00198-016-3894-y CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Alliance NBH (2016) National Bone Health Alliance: Strong Bones America. http://www.nbha.org/
- 20.https://www.iofbonehealth.org/osteoporosis-european-community-action-plan. Accessed 12 Mar 2018
- 22.Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S, Treatment of Osteoporosis in clinical Practice Study G (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17(6):914–921. https://doi.org/10.1007/s00198-006-0073-6 CrossRefPubMedGoogle Scholar
- 23.Korownyk C, Kolber MR, McCormack J, Lam V, Overbo K, Cotton C, Finley C, Turgeon RD, Garrison S, Lindblad AJ, Banh HL, Campbell-Scherer D, Vandermeer B, Allan GM (2014) Televised medical talk shows–what they recommend and the evidence to support their recommendations: a prospective observational study. BMJ 349:g7346. https://doi.org/10.1136/bmj.g7346 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative I (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMedGoogle Scholar
- 35.Kim SC, Kim DH, Mogun H, Eddings W, Polinski JM, Franklin JM, Solomon DH (2016) Impact of the US Food and Drug Administration’s safety-related announcements on the use of bisphosphonates after hip fracture. J Bone Miner Res 31(8):1536–1540. https://doi.org/10.1002/jbmr.2832 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https://doi.org/10.1007/s11657-013-0136-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Wilkinson E (2010) Calcium pills ‘increase’ risk of heart attack. http://www.bbc.co.uk/news/health-10805062. Accessed 9 Aug 2011
- 43.Kolata G (2016) Fearing drugs’ rare side effects, millions take their chances with osteoporosis. https://www.nytimes.com/2016/06/02/health/osteoporosis-drugs-bones.html
- 45.Kopecky SL, Bauer DC, Gulati M, Nieves JW, Singer AJ, Toth PP, Underberg JA, Wallace TC, Weaver CM (2016) Lack of evidence linking calcium with or without vitamin D supplementation to cardiovascular disease in generally healthy adults: a clinical guideline from the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Ann Intern Med 165(12):867–868. https://doi.org/10.7326/M16-1743 CrossRefPubMedGoogle Scholar
- 46.Cipriani C, Castro C, Curione M, Piemonte S, Biamonte F, Savoriti C, Pepe J, De Lucia F, Clementelli C, Nieddu L, Minisola S (2015) Acute effect of zoledronic acid on the risk of cardiac dysrhythmias. Intern Emerg Med 10(2):151–156. https://doi.org/10.1007/s11739-014-1125-0 CrossRefPubMedGoogle Scholar
- 47.Corbett JMMM (1999) Medicine, media, and celebrities: news coverage of breast cancer, 1960–1995. J Commun Q 76(2):229–249Google Scholar